Nov 07, 2016 4:30pm EST SCYNEXIS, Inc. Reports Third Quarter 2016 Financial Results and Provides Company Update
Oct 25, 2016 9:05am EDT SCYNEXIS Completes Two Additional Clinical Studies Further Supporting the Favorable Safety Profile of SCY-078
Oct 05, 2016 4:15pm EDT SCYNEXIS Announces Complete Results from Two Phase 2 Studies of Oral SCY-078 in Patients with Candida spp. Infections and Closing of a $15 Million Term Loan
Aug 24, 2016 9:05am EDT SCYNEXIS, Inc. Receives Orphan Drug Designation for SCY-078 for the Treatment of Invasive Aspergillus Infections
Aug 08, 2016 9:05am EDT SCYNEXIS, Inc. Reports Second Quarter 2016 Financial Results and Provides Company Update
Aug 01, 2016 8:00am EDT SCYNEXIS Announces Interim Results from Phase 2 Study of Oral SCY-078 in Patients with Invasive Candidiasis
Jul 13, 2016 8:30am EDT SCYNEXIS, Inc. Announces Sale of Cyclophilin Inhibitor Assets to Cypralis Limited
